Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis

• Published in: Nutrition, metabolism, and cardiovascular diseases Vol. 27; no. 12; pp. 1081 - 1088
• Main Authors: Gargiulo, P., Savarese, G., D'Amore, C., De Martino, F., Lund, L.H., Marsico, F., Dellegrottaglie, S., Marciano, C., Trimarco, B., Perrone-Filardi, P.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.12.2017
• Subjects: Cardiovascular events; Diabetes mellitus; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - mortality; Diabetic Angiopathies - blood; Diabetic Angiopathies - etiology; Diabetic Angiopathies - mortality; Diabetic Angiopathies - prevention & control; Glucagon-Like Peptide 1 - agonists; Glucagon-Like Peptide 1 - metabolism; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Incretins - adverse effects; Incretins - therapeutic use; Macrovascular events; Medicin och hälsovetenskap; Microvascular events; Nephropathy; Retinopathy; Risk Assessment; Risk Factors; Signal Transduction - drug effects; Treatment Outcome; Macrovascular events; Cardiovascular events; Retinopathy; GLP-1; Diabetes mellitus; DPP-4; DM; Microvascular events; CIs; RRs; Nephropathy; CV; MI; HbA1c; HF; Glucagon-like peptide-1 agonists

Glucagon-like peptide-1 (GLP-1) agonists improve glycaemic control in type 2 diabetes mellitus (DM). Outcome trials investigating macro and microvascular effects of GLP-1 agonists reported conflicting results. The aim of this study was to assess, in a meta-analysis, the effects of GLP-1 agonists on...